3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Gliosarcoma
3
Glioblastoma
3
Neoplasms
2
Brain Neoplasms
2
Recurrence
1
Glioma
1
Interventions
Cyclophosphamide
39
Peripheral Blood Stem Cell Transplantation
32
fludarabine phosphate
30
Busulfan
26
Filgrastim
24
Cyclosporine
24
Mycophenolic Acid
22
Antilymphocyte Serum
22
Radiotherapy
20
Melphalan
16
Whole-Body Irradiation
15
Tacrolimus
14
Methylprednisolone
14
Methotrexate
13
Cord Blood Stem Cell Transplantation
12
Etoposide
10
sargramostim
5
Thiotepa
5
Temozolomide
5
Sirolimus
5
Rituximab
5
Bevacizumab
5
aldesleukin
4
Therapeutics
4
Granulocyte Colony-Stimulating Factor
4
Cytarabine
4
Carmustine
4
pembrolizumab
3
Vincristine
3
Topotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
rindopepimut
×
Sarcoma
×
Clear all
NCT01498328
2020-02-17
ReACT
Celldex Therapeutics
Phase 2
Completed
127 enrolled